Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9981918-B2
Application number	US-201214241374-A
Country	US
Kind code	B2
Filing date	Aug 28, 2012
Priority date	Aug 30, 2011
Publication date	May 29, 2018
Grant date	May 29, 2018

Abstract

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

First claim

What is claimed:

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable excipient.

3. A method of treating Huntington's disease in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of the compound of claim 1 .

Assignees

• Toledo Sherman Leticia M
• Dominguez Celia
• Prime Michael
• Johnson Peter
• Munoz Sanjuan Ignacio
• Courtney Stephen Martin
• Mitchell William
• Brown Christopher John
• De Aguiar Pena Paula C
• Chdi Foundation Inc

Inventors

• Toledo-Sherman Leticia M
• Dominguez Celia
• Prime Michael
• Johnson Peter
• Muñoz-Sanjuán Ignacio
• Courtney Stephen Martin
• Mitchell William
• Brown Christopher John
• De Aguiar Pena Paula C

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title